Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update
02 avr. 2024 07h30 HE
|
Phio Pharmaceuticals Corp.
– Four sites across the country participating in clinical trial for lead product candidate PH-762 – Two patients have already completed treatment – New patent granted for skin related treatments,...
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
25 mars 2024 17h45 HE
|
Marker Therapeutics
Lead program in patients with lymphoma demonstrated preliminary safety and efficacy results with sustained complete response in first study participant treated with MT-601 (Neldaleucel) following CAR...
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
22 mars 2024 12h30 HE
|
Marker Therapeutics
HOUSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
21 mars 2024 07h30 HE
|
Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is...
Immatics Announces Full Year 2023 Financial Results and Corporate Update
21 mars 2024 07h00 HE
|
https://immatics.com/
Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objective response rate with median duration of response not reached at median...
Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research
13 mars 2024 14h00 HE
|
Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is...
Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disorders
06 mars 2024 10h30 HE
|
Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is...
Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
31 janv. 2024 08h00 HE
|
Phio Pharmaceuticals Corp.
--New preclinical data to be presented at Immunotherapy Conference in Germany MARLBOROUGH, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage...
Immatics Announces Pricing of $175 Million Public Offering
17 janv. 2024 20h30 HE
|
https://immatics.com/
Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T...
Immatics Announces Proposed Public Offering
17 janv. 2024 16h01 HE
|
https://immatics.com/
Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T...